Dr Julie Martyn

Project Manager
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5092
Fax +61 2 9565 1863

Map

Selected grants

2014

  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Shannon C, Martyn J, Yip S; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • ECHO trial: Exercise during Chemotherapy for Ovarian cancer; Hayes S, Friedlander M, Obermair A, Mileshkin L, Janda M, Gordon L, Barnes E, Beesley V, Sommeijer D, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • Does Palliative Chemotherapy Palliate? Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101); Friedlander M, Sjoquist K, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • Value of serum levels of Inhibin A, inhibin B, total inhibin and anti- Mullerian Hormone ( AMH) in measuring response of recurrent Granulosa cell tumours to Anastrazole; Friedlander M, Sjoquist K, Robertson D, BURGER H, Martyn J; Ovarian Cancer Research Foundation/Research Support.
  • REZOLVE: A Phase II study to evaluate the safety and potential palliative benefit of intraperitoneal bevacizumab in patients with symptomatic ascites due to advanced chemotherapy resistant gynaecological cancers; Sjoquist K, Friedlander M, Quinn M, Bowtell D, Mileshkin L, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • ICON8: An international multi-stage randomised phase III trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy for women with newly diagnosed epithelial ovarian cancer; Friedlander M, Quinn M, Mileshkin L, Ledermann J, Clamp A, Dean A, Beale P, Sjoquist K, Martyn J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.
  • A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The OUTBACK trial; Mileshkin L, Narayan K, Rischin D, Quinn M, Friedlander M, Moore K, Kitchener H, Shrivastava S, Martyn J, Small Jnr W; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • PORTEC-3 - the role of adjuvant chemotherapy in high-risk endometrial cancer; Mileshkin L, Quinn M, Khaw P, Stockler M, Brand A, Martyn J, Sjoquist K, Creutzberg C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2011

  • Study to evaluate the safety and efficacy of intraperitoneal bevacizumab in patients with advanced platinum refractory or resistant ovarian cancer and symptomatic ascites; Friedlander M, Sjoquist K, Martyn J; DVC Research/Cancer Research Fund.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]
  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]
  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]

2013

  • Blinman, P., Gainford, C., Donoghoe, M., Martyn, J., Bloomfield, P., Grant, P., Kichenadasse, G., Vaughan, M., Brand, A., Shannon, C., Gebski, V., Stockler, M., et al (2013). Feasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study. Journal of Gynecologic Oncology, 24(4), 359-366. [More Information]
  • Sjoquist, K., Friedlander, M., O'Connell, R., Voysey, M., King, M., Stockler, M., Oza, A., Gillies, K., Martyn, J., Butow, P. (2013). Hope, Quality of Life, and Benefit From Treatment in Women Having Chemotherapy for Platinum-Resistant/Refractory Recurrent Ovarian Cancer: The Gynecological Cancer Intergroup Symptom Benefit Study. The Oncologist, 18(11), 1221-1228. [More Information]

2011

  • Sjoquist, K., Martyn, J., Edmondson, R., Friedlander, M. (2011). The role of hormonal therapy in gynecological cancers-current status and future directions. International Journal Of Gynecological Cancer, 21(7), 1328-1333. [More Information]

2009

  • Friedlander, M., Butow, P., Stockler, M., Gainford, C., Martyn, J., Oza, A., Donovan, H., Miller, B., King, M. (2009). Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. International Journal Of Gynecological Cancer, 19(Suppl 2), S44-S48. [More Information]

To update your profile click here. For support on your academic profile contact .